- Home
- MYGN vs IRS Comparison
MYGN vs IRS Comparison
Compare MYGN & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- IRS
- Stock Information
- Founded
- MYGN 1991
- IRS 1943
- Country
- MYGN United States
- IRS Argentina
- Employees
- MYGN N/A
- IRS N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IRS Homebuilding
- Sector
- MYGN Health Care
- IRS Real Estate
- Exchange
- MYGN Nasdaq
- IRS Nasdaq
- Market Cap
- MYGN 1.2B
- IRS 1.1B
- IPO Year
- MYGN 1995
- IRS 1994
- Fundamental
- Price
- MYGN $14.18
- IRS $14.15
- Analyst Decision
- MYGN Hold
- IRS Strong Buy
- Analyst Count
- MYGN 13
- IRS 1
- Target Price
- MYGN $22.54
- IRS $12.62
- AVG Volume (30 Days)
- MYGN 1.2M
- IRS 158.2K
- Earning Date
- MYGN 02-24-2025
- IRS 02-07-2025
- Dividend Yield
- MYGN N/A
- IRS 11.59%
- EPS Growth
- MYGN N/A
- IRS N/A
- EPS
- MYGN N/A
- IRS N/A
- Revenue
- MYGN $823,600,000.00
- IRS $325,094,048.00
- Revenue This Year
- MYGN $13.60
- IRS N/A
- Revenue Next Year
- MYGN $3.25
- IRS N/A
- P/E Ratio
- MYGN N/A
- IRS N/A
- Revenue Growth
- MYGN 12.15
- IRS N/A
- 52 Week Low
- MYGN $12.04
- IRS $7.32
- 52 Week High
- MYGN $29.30
- IRS $17.67
- Technical
- Relative Strength Index (RSI)
- MYGN 55.82
- IRS 46.29
- Support Level
- MYGN $14.13
- IRS $13.85
- Resistance Level
- MYGN $15.47
- IRS $14.40
- Average True Range (ATR)
- MYGN 0.72
- IRS 0.72
- MACD
- MYGN 0.27
- IRS 0.08
- Stochastic Oscillator
- MYGN 61.38
- IRS 69.07
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.